Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)

Hilary M. DuBrock, Hayley D. Germack, Marjolaine Gauthier-Loiselle (), Jörg Linder, Ambika Satija, Ameur M. Manceur, Martin Cloutier, Patrick Lefebvre, Sumeet Panjabi and Robert P. Frantz
Additional contact information
Hilary M. DuBrock: Mayo Clinic
Hayley D. Germack: Medical Affairs, Johnson and Johnson Innovative Medicines
Marjolaine Gauthier-Loiselle: Analysis Group, Inc.
Jörg Linder: Janssen-Cilag GmbH
Ambika Satija: Analysis Group, Inc.
Ameur M. Manceur: Analysis Group, Inc.
Martin Cloutier: Analysis Group, Inc.
Patrick Lefebvre: Analysis Group, Inc.
Sumeet Panjabi: Medical Affairs, Johnson and Johnson Innovative Medicines
Robert P. Frantz: Mayo Clinic

PharmacoEconomics - Open, 2024, vol. 8, issue 1, No 12, 133-146

Abstract: Abstract Background The aim of this study was to assess health care resource utilization (HRU) and costs associated with delayed pulmonary arterial hypertension (PAH) diagnosis in the United States. Methods Eligible adults with newly diagnosed PAH from Optum’s de-identified Clinformatics® Data Mart Database (2016–2021) were assigned to mutually exclusive cohorts based on time between first PAH-related symptom and first PAH diagnosis (i.e., ≤12 months’ delay, >12 to ≤24 months’ delay, >24 months’ delay). All-cause HRU and health care costs per patient per month (PPPM) were assessed during the first year following diagnosis and compared across cohorts using regression analysis adjusted for baseline covariates. Sensitivity analyses were conducted to assess outcomes during all available follow-up post-diagnosis. Results Among 538 patients (mean age: 65.6 years; 60.6% female), 60.8% had ≤12 months’ delay, 23.4% had a delay of >12 to ≤24 months, and 15.8% had >24 months’ delay. Compared with ≤12 months, delays of >12 to ≤24 months and >24 months were associated with increased hospitalizations (incidence rate ratio [95% confidence interval]: 1.40 [1.11–1.71] vs 1.71 [1.29–2.12]) and outpatient visits (1.17 [1.06–1.30] vs 1.26 [1.08–1.41]). Longer delays were also associated with more intensive care unit (ICU) stays and 30-day readmissions. Diagnosis delays translated into excess costs PPPM of US$3986 [1439–6436] for >12 to ≤24 months and US$5366 [2107–8524] for >24 months compared with ≤12 months’ delay; increased hospitalization costs (US$3248 [1108–5135] and US$4048 [1401–6342], respectively) being the driver. Sensitivity analyses yielded similar trends. Conclusions Delayed PAH diagnosis is associated with significant incremental economic burden post-diagnosis, driven by hospitalizations including ICU stays and 30-day readmissions, highlighting the need for increased awareness and a potential benefit of earlier screening.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-023-00453-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:1:d:10.1007_s41669-023-00453-8

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-023-00453-8

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().